$AAGH
America Great Health

2023 Q3 Form 10-Q Financial Statement

#000118518523001220 Filed on November 17, 2023

View on sec.gov

Income Statement

Concept 2023 Q3
Revenue $13.81K
YoY Change -73.41%
Cost Of Revenue $177.00
YoY Change -99.36%
Gross Profit $13.63K
YoY Change -44.22%
Gross Profit Margin 98.72%
Selling, General & Admin $88.57K
YoY Change -41.98%
% of Gross Profit 649.76%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $3.697K
YoY Change 150.47%
% of Gross Profit 27.12%
Operating Expenses $88.57K
YoY Change -41.98%
Operating Profit -$74.94K
YoY Change -41.56%
Interest Expense $82.05K
YoY Change 27.13%
% of Operating Profit
Other Income/Expense, Net -$82.04K
YoY Change 27.13%
Pretax Income -$157.0K
YoY Change -18.56%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$157.0K
YoY Change -18.56%
Net Earnings / Revenue -1136.88%
Basic Earnings Per Share
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 21.11B shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $54.63K
YoY Change -26.74%
Cash & Equivalents $54.63K
Short-Term Investments
Other Short-Term Assets $16.97K
YoY Change 0.0%
Inventory $108.2K
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $179.8K
YoY Change -15.88%
LONG-TERM ASSETS
Property, Plant & Equipment $54.00K
YoY Change 143.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $8.218K
YoY Change -75.86%
Total Long-Term Assets $97.15K
YoY Change -30.85%
TOTAL ASSETS
Total Short-Term Assets $179.8K
Total Long-Term Assets $97.15K
Total Assets $276.9K
YoY Change -21.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.448M
YoY Change 0.96%
Accrued Expenses $23.10K
YoY Change -65.44%
Deferred Revenue
YoY Change
Short-Term Debt $690.6K
YoY Change 350.35%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.150M
YoY Change 13.25%
LONG-TERM LIABILITIES
Long-Term Debt $1.123M
YoY Change -0.79%
Other Long-Term Liabilities $684.0K
YoY Change 44.48%
Total Long-Term Liabilities $1.123M
YoY Change -0.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.150M
Total Long-Term Liabilities $1.123M
Total Liabilities $4.957M
YoY Change 12.99%
SHAREHOLDERS EQUITY
Retained Earnings -$9.339M
YoY Change 8.55%
Common Stock $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.605M
YoY Change
Total Liabilities & Shareholders Equity $276.9K
YoY Change -21.81%

Cashflow Statement

Concept 2023 Q3
OPERATING ACTIVITIES
Net Income -$157.0K
YoY Change -18.56%
Depreciation, Depletion And Amortization $3.697K
YoY Change 150.47%
Cash From Operating Activities -$120.8K
YoY Change -15.66%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $118.5K
YoY Change -23.59%
NET CHANGE
Cash From Operating Activities -$120.8K
Cash From Investing Activities $0.00
Cash From Financing Activities $118.5K
Net Change In Cash $476.00
YoY Change -96.01%
FREE CASH FLOW
Cash From Operating Activities -$120.8K
Capital Expenditures $0.00
Free Cash Flow -$120.8K
YoY Change -15.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Document Type
DocumentType
10-Q
CY2023Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q3 dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
CY2023Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q3 dei Entity File Number
EntityFileNumber
000-27873
CY2023Q3 dei Entity Registrant Name
EntityRegistrantName
America Great Health
CY2023Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WY
CY2023Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0178621
CY2023Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
1609 W Valley Blvd Unit 338A
CY2023Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
Alhambra
CY2023Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91803
CY2023Q3 dei City Area Code
CityAreaCode
(888)
CY2023Q3 dei Local Phone Number
LocalPhoneNumber
988-1333
CY2023Q3 dei Security12b Title
Security12bTitle
N/A
CY2023Q3 dei No Trading Symbol Flag
NoTradingSymbolFlag
true
CY2023Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2023Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
CY2023Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21107018148 shares
CY2023Q3 us-gaap Cash
Cash
54626 usd
CY2023Q2 us-gaap Cash
Cash
54150 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
108174 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
108351 usd
CY2023Q3 us-gaap Advances On Inventory Purchases
AdvancesOnInventoryPurchases
16965 usd
CY2023Q2 us-gaap Advances On Inventory Purchases
AdvancesOnInventoryPurchases
16964 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
179765 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
179465 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23104 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
41918 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8218 usd
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8218 usd
CY2023Q3 us-gaap Deposit Assets
DepositAssets
11836 usd
CY2023Q2 us-gaap Deposit Assets
DepositAssets
11836 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53995 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
57692 usd
CY2023Q3 us-gaap Assets
Assets
276918 usd
CY2023Q2 us-gaap Assets
Assets
299129 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1448030 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1450574 usd
CY2023Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
3410 usd
CY2023Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
3970 usd
CY2023Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
690551 usd
CY2023Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
705216 usd
CY2023Q3 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
275948 usd
CY2023Q2 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
241784 usd
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
484248 usd
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
425142 usd
CY2023Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
224570 usd
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
223331 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
23104 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
41918 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3149861 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3091935 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2023Q3 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
683957 usd
CY2023Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
609892 usd
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1123138 usd
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1123138 usd
CY2023Q3 us-gaap Liabilities
Liabilities
4956956 usd
CY2023Q2 us-gaap Liabilities
Liabilities
4824965 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21107018148 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21107018148 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21090218148 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21090218148 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4732477 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4732477 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2278 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-500 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9339487 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9183110 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-4604732 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-4451133 usd
CY2023Q3 us-gaap Minority Interest
MinorityInterest
-75306 usd
CY2023Q2 us-gaap Minority Interest
MinorityInterest
-74703 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4680038 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4525836 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
276918 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
299129 usd
CY2023Q3 us-gaap Revenues
Revenues
13808 usd
CY2022Q3 us-gaap Revenues
Revenues
51938 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
177 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
27500 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
13631 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
24438 usd
CY2023Q3 us-gaap Selling Expense
SellingExpense
64 usd
CY2022Q3 us-gaap Selling Expense
SellingExpense
4736 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
88505 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
147923 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
88569 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
152659 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-74938 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-128221 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
82049 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
64539 usd
CY2023Q3 us-gaap Other Income
OtherIncome
7 usd
CY2022Q3 us-gaap Other Income
OtherIncome
6 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-82042 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-64533 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-156980 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-192754 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-156980 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-192754 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-603 usd
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-10418 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-156377 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-182336 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2278 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
76 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-154099 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-182260 usd
CY2023Q3 aagh Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
0
CY2022Q3 aagh Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
0
CY2023Q3 aagh Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
21093818148 shares
CY2022Q3 aagh Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
21090218148 shares
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3860481 usd
CY2022Q3 aagh Imputed Interest
ImputedInterest
5206 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
15200 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
76 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-192754 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4032753 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4525836 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2778 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-156980 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4680038 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-156980 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-192754 usd
CY2023Q3 us-gaap Depreciation
Depreciation
3697 usd
CY2022Q3 us-gaap Depreciation
Depreciation
1476 usd
CY2023Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
CY2022Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
15200 usd
CY2023Q3 aagh Imputed Interest
ImputedInterest
0 usd
CY2022Q3 aagh Imputed Interest
ImputedInterest
5206 usd
CY2023Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
CY2022Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-273 usd
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0 usd
CY2022Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0 usd
CY2023Q3 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
0 usd
CY2022Q3 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
0 usd
CY2022Q3 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
20210 usd
CY2023Q3 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-177 usd
CY2022Q3 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5447 usd
CY2023Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2544 usd
CY2022Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3280 usd
CY2023Q3 us-gaap Increase Decrease In Customer Advances
IncreaseDecreaseInCustomerAdvances
1240 usd
CY2022Q3 us-gaap Increase Decrease In Customer Advances
IncreaseDecreaseInCustomerAdvances
13000 usd
CY2022Q3 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
27137 usd
CY2023Q3 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
33602 usd
CY2022Q3 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
16143 usd
CY2022Q3 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
12 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-120808 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-143244 usd
CY2023Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
CY2022Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023Q3 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
-14664 usd
CY2022Q3 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
-30595 usd
CY2023Q3 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
74064 usd
CY2022Q3 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
152924 usd
CY2023Q3 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
77470 usd
CY2022Q3 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
104706 usd
CY2023Q3 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
18364 usd
CY2022Q3 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
71938 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
118506 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
155097 usd
CY2023Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2778 usd
CY2022Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
476 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11929 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54150 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62643 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54626 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
74572 usd
CY2023Q3 us-gaap Interest Paid
InterestPaid
0 usd
CY2022Q3 us-gaap Interest Paid
InterestPaid
0 usd
CY2023Q3 us-gaap Income Taxes Paid
IncomeTaxesPaid
800 usd
CY2022Q3 us-gaap Income Taxes Paid
IncomeTaxesPaid
800 usd
CY2023Q3 us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
0 usd
CY2022Q3 us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
0 usd
CY2017Q1 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
16155746000 shares
CY2017Q1 us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
100 usd
CY2020Q2 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
510000000 shares
CY2021Q3 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
50000 usd
CY2021Q3 us-gaap Number Of Units In Real Estate Property
NumberOfUnitsInRealEstateProperty
53 pure
CY2021Q3 us-gaap Number Of Real Estate Properties
NumberOfRealEstateProperties
19 pure
CY2021Q3 us-gaap Real Estate Gross At Carrying Value
RealEstateGrossAtCarryingValue
7626286.37 usd
CY2021Q3 us-gaap Payments To Acquire Real Estate
PaymentsToAcquireRealEstate
7000000 usd
CY2021Q3 aagh Real Estate Description Of Terms
RealEstateDescriptionOfTerms
$1,000,000 on execution of the Agreement, (ii) $2,000,000 within 60 days thereof and (iii) the remainder by April 10, 2022. The Agreement is subject to customary closing conditions, including, satisfactory due diligence. On September 9, 2021, the Company entered into a Supplemental Assets Acquisition Agreement with Wang’s Property Investment & Management LLC to amend and clarify that (i) it was purchasing 19 real estate properties which includes 53 units appraised at $7,626,286.37 for a purchase price of $7,000,000 and (ii) that it will waive and not conduct due diligence in order for the transaction to proceed. The acquisition has not been consummated.
CY2021Q4 aagh Class Of Warrant Or Rights Granted
ClassOfWarrantOrRightsGranted
500000 shares
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2021Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P24M
CY2022Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
500000 shares
CY2021Q4 us-gaap Investment Owned Balance Shares
InvestmentOwnedBalanceShares
20000000 shares
CY2022Q4 aagh Agreement Description
AgreementDescription
The Company A agrees that if the patent is sold or transferred, Men Hwei, Tsai or Men Hwei, Tsai's successor may receive a 25% gain on the transfer or sale of the interest. The Company agrees to give Men Hwei, Tsai an additional 20 million AAGH shares. The Company allows Men Hwei, Tsai to use three years (from November 26, 2022 to November 25, 2025) find investors each with more than US$10 million investment. In case that no investor is found within three years, Men Hwei, Tsai agrees to return the patent to the Company, and both parties will continue to cooperate in accordance with the original contract on May 18, 2021. If Men Hwei, Tsai finds an investor with an investment of at least US$10 million within three years, and the process for Men Hwei, Tsai and its investors to apply for a new drug may last for several years, then Men Hwei, Tsai agrees that the Company will use the patented technology to develop dietary supplement that are helpful to Alzheimer’s disease. The Company will be responsible for marketing the dietary supplement. Men Hwei, Tsai is entitled to commission equaling to 8% of sales price.
CY2022Q4 us-gaap Other Commitment
OtherCommitment
34978.48 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-156980 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-120808 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4680038 usd
CY2023Q3 us-gaap Cash
Cash
54626 usd
CY2023Q2 us-gaap Other Receivables
OtherReceivables
11836 usd
CY2023Q3 us-gaap Other Receivables
OtherReceivables
11836 usd
CY2023Q3 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Estimates</b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services, debt and equity investment. Actual results could differ from those estimates.</p>
CY2023Q3 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
1 pure
CY2023Q3 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
1 pure
CY2023Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
3884 usd
CY2023Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
4087 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
108174 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
108351 usd
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
65900 usd
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
65900 usd
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
42274 usd
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
42451 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
108174 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
108351 usd
CY2023Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
690551 usd
CY2023Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
705216 usd
CY2023 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
1123138 usd
CY2023Q3 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
1123138 usd
CY2023Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.20 pure
CY2022Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.16 pure
CY2023Q3 us-gaap Long Term Debt Term
LongTermDebtTerm
P5Y
CY2023Q3 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
1123138 usd
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
459079 usd
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
1582217 usd
CY2021Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.20 pure
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
20277 usd
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21107018148 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21107018148 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21090218148 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21090218148 shares
CY2022Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1300000 shares
CY2022Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.075
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
18896 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y14D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.05 pure
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
23423 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
14603 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
8820 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
0 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
23423 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
319 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
23104 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
23104 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2023Q3 dei Amendment Flag
AmendmentFlag
false
CY2023Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2023Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001098009

Files In Submission

Name View Source Status
0001185185-23-001220-index-headers.html Edgar Link pending
0001185185-23-001220-index.html Edgar Link pending
0001185185-23-001220.txt Edgar Link pending
0001185185-23-001220-xbrl.zip Edgar Link pending
aagh-20230930.xsd Edgar Link pending
amgreat20230930_10q.htm Edgar Link pending
ex_597794.htm Edgar Link pending
ex_597795.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
aagh-20230930_cal.xml Edgar Link unprocessable
aagh-20230930_lab.xml Edgar Link unprocessable
aagh-20230930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
amgreat20230930_10q_htm.xml Edgar Link completed
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
aagh-20230930_pre.xml Edgar Link unprocessable